The Ritedose Corporation Begins Production of Drug to Alleviate National Medication Shortage

COLUMBIA, S.C. (April 25, 2023) – The Ritedose Corporation (Ritedose), an industry leader in pharmaceutical development, aseptic cGMP manufacturing and 503B outsourcing solutions, has begun production of a particular form of Albuterol Sulfate that the FDA has listed in short supply in the United States. It will be available in May.

Continue reading

Ritedose Pharmaceuticals Launches New Product: <em>Arformoterol Tartrate Inhalation Solution (15 mcg/2 ml)</em>

COLUMBIA, S.C. (April 13, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose oral inhalation product, Arformoterol Tartrate (15 mcg/2 ml), making the company the largest generic drug maker of its kind. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a

Continue reading

Ritedose Awarded 503B Compounded Medications Agreement with Premier, Inc.

COLUMBIA, S.C. (January 30, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, has been awarded a group purchasing agreement with Premier Inc., a leading healthcare improvement company operating one of the nation’s largest group purchasing organizations (GPOs). Effective January 1, 2023, the new agreement allows Premier members,

Continue reading

Ritedose Launches Two New Single-Dose Syringe Products Amid National Drug Shortage: <em>Bupivacaine Hydrocholoride 0.25% (2.5 mg/mL) and Bupivacaine Hydrocholoride 0.5% (5 mg/mL)</em>

COLUMBIA, S.C. (November 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched two new unit dose syringe products, Bupivacaine Hydrocholoride 0.25% (2.5 mg/mL) and Bupivacaine Hydrocholoride 0.5% (5 mg/mL). They are ready-to-use drug shortage solutions for hospital pharmacies across the country. Ritedose is a division

Continue reading

Ritedose Launches Critical Single-Dose Syringe Product Amid National Drug Shortage: <em>Lidocaine Hydrochloride 1% 100 mg/10 mL</em>

COLUMBIA, S.C. (October 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Lidocaine Hydrochloride 1% 100 mg/10 mL. It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation,

Continue reading

Ritedose Launches New 503B, Single-Dose Syringe Medications for Hospitals: <em>Rocuronium Bromide Injection (50 mg/5mL) and Rocuronium Bromide Injection (100 mg/10mL)</em>

COLUMBIA, S.C. (February 14, 2022) – Ritedose, a 25-year industry veteran in pharmaceutical development and cGMP manufacturing, just launched two new 503B critical care, unit dose syringe products – Rocuronium Bromide Injection 50 mg/5mL and Rocuronium Bromide Injection 100 mg/10mL. Ritedose 503B Outsourcing Facility is a division of Ritedose.

Continue reading

Ritedose Pharmaceuticals Launches Cromolyn Sodium Oral Solution (Concentrate) 100 mg/5 ml

COLUMBIA, S.C. (January 5, 2022) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product, Cromolyn Sodium Oral Solution (Concentrate), 100 mg/5 ml. The oral solution is the first of a new product line for Ritedose Pharmaceuticals which has historically offered a

Continue reading

Ritedose Pharmaceuticals Launches Budesonide Inhalation Suspension (0.5 mg/2 ml)

COLUMBIA, S.C. (December 29, 2021) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product for hospitals, Budesonide Inhalation Suspension (0.5 mg/2 ml). It is the first of five new inhalation products scheduled for release by March 2022. Ritedose Pharmaceuticals is a

Continue reading

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL)</em>

COLUMBIA, S.C. (September 10, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL). It is the last of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is

Continue reading

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Epinephrine Injection 1 mg/10 mL (0.1 mg/mL)</em>

COLUMBIA, S.C. (August 24, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Epinephrine Injection 1 mg/10 mL (0.1 mg/mL). It is the 11th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a

Continue reading